John Jose, Asishkumar Mandalay, Manjunath N Cholenahally, Ravindranath S Khandenahally, Srinivas C Budnur, Maulik Parekh, Ravinder S Rao, Ashok Seth, Praveen Chandra, Rajneesh Kapoor, Praveer Agarwal, Atul Mathur, Vijay Kumar, Sadananda S Kanchanahalli, Ajith S Mullasari, Vijayakumar Subban, Uday B Khanolkar, Sanjay Mehrotra, Manik Chopra, Rajendra K Jain, Haresh Mehta, Rahul Gupta, Viveka Kumar, Bagirath Raghuraman, Naman Shastri, Hesham Elzomor, Osama Soliman, Sengottuvelu Gunasekaran
PURPOSE: To evaluate the safety and effectiveness of the novel, next-generation Myval Octacor - Transcatheter Heart Valve (THV) in patients with severe, symptomatic, native aortic stenosis (AS). METHODS: This multicenter, real-world observational registry included 123 patients with severe symptomatic AS, across 16 Indian centers who underwent treatment with the novel Myval Octacor THV. Study endpoints included all-cause mortality, all stroke, acute kidney injury (AKI), major vascular complications, moderate or severe paravalvular leakage (PVL) and new permanent pacemaker implantation (PPI) until 30 days follow-up...
January 28, 2024: Cardiovascular Revascularization Medicine: Including Molecular Interventions